Otsuka Q1 revenue jumps amid Araris acquisition, share buyback

** Otsuka Holdings (TSE:4578) reported a 12.2% year-over-year increase in revenue to ¥582.84B for the first quarter of 2025, driven by growth in its pharmaceutical and nutraceutical businesses. Business profit rose by 38.2% to ¥122.95B. The pharmaceutical segment saw gains from key products, including REXULTI and LONSURF, alongside growth in long-acting injectables. In the nutraceuticals segment, gains were mainly driven by the women's health and healthy life categories.